News
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms a
CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public offerings of 8,584,375 shares of common stock at a public offering price of $64.00 per share, pre-funded warrants to purchase 400,000 shares of common stock at a public offering price of $63.999 per pre-funded warrant and $575 million aggregate principal amount of 1.50% convertible s
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
Preclinical Results at Sheba Medical Center Demonstrate Retinal Recovery with NurExone’s Exosome-based Lead Candidate TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes (exosomes without added therapeutic cargo) and
AB Science today reports its revenues for the first half of 2026 and provides an update on its activities
PRESS RELEASE AB SCIENCE REPORTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2026 AND KEY EVENTS OF THE PERIOD Change in AB Science's governance and implementation of a new strategy Appointment of Stéphane Ledermann as Chairman and Chief Executive Officer In-depth overhaul of the Company's organisation and strategy Priority given to the development of a new quality assurance system Web conference to be held on Wednesday 14 October 2026 at 6:00 pm to present the Company's new ambitions in detail
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of - In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices - RADNOR, Pa., Oct. 09, 2026 (GLOBE
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 MIRAMAR, Fla., Oct. 09, 2026 (GLOBE NEWSWIRE) -- HCW Biologic
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York. 2026 Maxim Growth Summit Conference Details: Format: One-on-one meetings Date: October 12
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R. Fandrick, Ph.D. Board strengthened with the addition of Catherine Bonuccelli, M.D., Leone Patterson, James Valentine, J.D., M.H.S., and Drayton Wise Cash balance of $116 million as of June 30, 2026 expected to fund operations through the end of 2028, supporting anticipated clinical data readou
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's efficacy and symptom improvements across the body in individuals with psoriasis Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis Real-world research examines the role long-term topical corticosteroid use plays in the c
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York. Conference Details: Panel Discussion: Immunology & Inflammation Therapies Presente
TestMu AI Positioned as a Leader in the 2026 Gartner® Magic Quadrant™ for Agentic Software Quality Assurance Platforms
Evaluation Based on Completeness of Vision and Ability to Execute NOIDA, India , Oct. 9, 2026 -- TestMu AI , the Full-Stack Agentic AI Quality Engineering platform, announced it has been positioned as a Leader in the 2026 Gartner Magic Quadrant for Agentic Software Quality Assurance Platforms. A complimentary copy of this research report is available [ here ]. As software delivery shifts toward agentic workflows, TestMu AI continues to advance end-to-end quality engineering through agentic testing and scalable cloud execution infrastructure. The platform provides independent verification, nondeterministic agent evaluation, and governance capabilities that allow enterprise teams to transition smoothly into agentic software delivery while maintaining existing browser and device testing environments.
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a c
Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026
MONTVALE, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 23, 2026, at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 23, 2026. The press release, and its accompanying financial exhibits, will also be
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Denifanstat showed continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks, including 57% IGA success, 72% reduction in total lesions, and 77% reduction in inflammatory lesions, and was generally well-tolerated Clinical findings and preclinical mechanistic evidence support FASN inhibition as a novel oral therapeutic approach targeting key aspects of acne pathogenesis AURORA U.S. Phase 3 trial screening patients, with sites activated and IRB approvals in place
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring required The approval is based on results from the pivotal Phase 3 SOLARIS trial, which demonstrated overall symptom improvement, significant reduction in illness severity and improvement in personal and s
A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib
First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM) Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomize
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching from placebo or apremilast achieved rapid responses, comparable to those on continuous treatment at Week 48 – On track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (
NTG Nordic Transport Group A/S - Q3 2026 Conference Call
NTG Nordic Transport Group A/S – Q3 2026 Conference Call We expect to release the Q3 2026 interim results of NTG Nordic Transport Group on the evening of November 9, 2026. A webcast and conference call will be held on the morning of November 10, 2026, at 10:00 am CET. At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Tinneke Torpe will present the Q3 2026 Interim Financial Report. The presentation will be followed by a Q&A session. Date: November 10, 2026 Time: 10:00 am CET To attend
HackerOne Report Highlights Challenges of 'Exposure Debt': NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK , Oct. 9, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today s NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on October 9th HackerOne released its 10 th annual Security Research Report this week. The report found that the backlog of validated, unresolved vulnerabilities grew by 131% in two years. Exposure Debt is at the focus of the report, which HackerOne defines as the growing gap between what organizations find and what they can fix. CEO Kara Sprague will join NYSE Live to dive deeper into the findings and discuss the impact of AI across cybersecurity. Zeta Global held its Zeta Live 26 event in New York City on Thursday. Zeta Global (NYSE: ZETA) announced that it teamed up with Fireworks to develop the Athena Inference Model. CEO David Steinberg spoke to the heightened enthusiasm for Zeta Global s work and the evolution of Athena in an interview that will air on NYSE Live. The major averages will look to bounce back as investors monitor the AI trade. A revenue report from OpenAI impacted market activity on Thursday. Elevated Treasury yields and oil prices continue to drive economic sentiment.
KONE Inaugurates India's First Digital Experience Centre in Pune to Advance Digital Innovation
New Centre showcases how AI, connectivity, data and digital solutions are transforming customer experiences and enabling smarter, more connected buildings PUNE, India , Oct. 9, 2026 -- KONE, a global leader in the elevator and escalator industry, today inaugurated India s first KONE Digital Experience Centre (DEC) in Pune, marking an important milestone in its digital transformation journey and commitment to creating exceptional customer experiences through technology, data and innovation. The Centre was jointly inaugurated by Jussi Herlin, Executive Vice Chair, KONE; Philippe Delorme, President and CEO, KONE along with Nandan Nilekani, Co-founder and Chairman of the Board, Infosys.
Chandigarh University Hosts National Incubator & Capital Summit and ISBACON 2026, Bringing 400 Incubators, 80 Investors & 100 Startups Together to Strengthen India's Startup Ecosystem
Chandigarh University Launches C-Hub Incubator of Incubators as National Consortium to Take Indian Startups from Ideas to Market CHANDIGARH, India , Oct. 9, 2026 -- Aimed at strengthening access to early-stage investment for startups by connecting India s incubation institutions with investors, industry and policymakers, Chandigarh University brought together more than 400 incubator institutions from more than 20 States and Union Territories, over 100 startups, 80 investors and more than 60 government, policy and industry delegates on a single platform at Incubator & Capital Summit 2026 and ISBACON 2026.
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone 1 First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage II
MIDEA COMPLETES THE ACQUISITION OF ESAOTE
Midea Group marks its commitment to healthcare and innovation by completing the acquisition of Esaote GENOA, Italy , Oct. 9, 2026 -- Esaote S.p.A., a leader in the medical imaging sector, announces the completion of the controlling stake acquisition of its share capital by Midea the Chinese global technology group headquartered in the district of Shunde, Foshan. The transaction is aimed at fostering synergies between Esaote and Midea s Healthcare Division to increase international competitiveness. Esaote will be part of Midea Healthcare and will continue to operate as an independent global medical equipment company, headquartered in Genoa, Italy, with R&D and manufacturing facilities in Italy and the Netherlands.
Charmacy Milano Celebrates 6th Birthday With Carnival Sale and Rs 1.8 Lakh Creator Hunt
Charmacy Milano Carnival Sale Begins October 12: Unlock Flat 20% OFF, 10% Cashback, and 9 Days of Daily Arcade Rewards Mumbai-based vegan, cruelty-free beauty brand hosts a 9-day festive event on charmacyworld.com from October 12-20. MUMBAI, India , Oct. 9, 2026 -- Mumbai-based vegan and cruelty-free colour cosmetics brand Charmacy Milano will mark its sixth birthday on October 18 by launching the Charmacy Carnival , a nine-day festive event running from October 12 to 20 on charmacyworld.com . The celebration will feature Flat 20% OFF, 10% Cashback, daily arcade rewards and a Rs 1.8 lakh creator hunt , along with a live makeup masterclass series.
Hisense Brings AI Companion Suite to Life with a Social Kitchen
QINGDAO, China , Oct. 9, 2026 -- Hisense, a leading brand in global consumer electronics and home appliances, is bringing its vision of Innovating a Brighter Life into the heart of the home with the new PureSmart Duo Series a refrigerator series designed as the intelligent center of the kitchen and now being rolled out across global markets. Building on the AI Companion Suite introduced at IFA 2026, Hisense is extending its vision of AI beyond appliances to create connected experiences across the home. Through the ConnectLife platform, the PureSmart Duo Series brings people, appliances and experiences together, making AI a more natural part of everyday life.
Astrogate Labs and Spacebeam Sign Strategic Partnership to Advance End-to-End Space-to-Ground Laser Communications
Indian laser communication terminal developer and South Korean optical ground station company to collaborate on interoperability demonstrations and OGS-as-a-Service and commercial optical communication solutions across India, the Republic of Korea and global markets BENGALURU, India , Oct. 9, 2026 -- Astrogate Labs , an Indian deep-tech company developing Free-Space Optical Communication (FSOC) systems for space applications, and Spacebeam Inc. , a South Korean optical communications company developing optical ground station infrastructure, have signed a Memorandum of Understanding (MoU) on Strategic Partnership to advance the validation, demonstration and commercialization of end-to-end space-to-ground laser communication solutions.
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to Retension from the offering, before de
TRexBio Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of $14.00 per share. All of the shares are being offered by TRexBio. The gross proceeds from the offering, before deducting
IMC 2026: From Connectivity to Deployment at Scale, Fibocom Strengthens Its IoT Presence in India
NEW DELHI , Oct. 9, 2026 -- Fibocom (300638.SZ; 0638.HK), a leading global provider of wireless communication modules and AI solutions, presented its latest portfolio at India Mobile Congress 2026, as growing adoption of 5G, energy digitalization and connected mobility creates new demand for IoT deployment across India. At the show, Fibocom highlighted applications spanning wireless broadband, energy, vehicle and asset management. Its FWA portfolio included 5G modules as well as CPE, ODU and MiFi solutions, while smart meters, vehicle tracking devices and EV battery trackers demonstrated how cellular connectivity is moving deeper into vertical applications.
SGS WINS SAF SUPPLY CHAIN EXCELLENCE AWARD AT INDIA SAF CONCLAVE & AWARDS 2026
NEW DELHI , Oct. 9, 2026 -- We are proud to announce that we have been recognized with the SAF Supply Chain Excellence Award Testing, Inspection, Verification & Quality Assurance at the India SAF Conclave & Awards 2026, held on September 29 at Bharat Mandapam, New Delhi. This prestigious recognition highlights our contribution to strengthening quality, integrity, transparency and confidence across the Sustainable Aviation Fuel (SAF) value chain through its testing, inspection, verification and quality assurance capabilities.
Embark and Tavant Partner to Enable AI-Ready Global Capability Centres in India
The partnership brings together Embark s end-to-end GCC setup and operations capabilities with Tavant s AI, data and digital engineering expertise to help enterprises build, scale and transform GCCs in India BENGALURU, India , Oct. 9, 2026 -- Embark , a premier, fully integrated service provider dedicated to accelerating the establishment and expansion of Global Capability Centres (GCCs) in India, and Tavant , a leading platform-powered AI transformation specialist, today announced a strategic partnership to help global enterprises design, build, operate and transform GCCs in India.
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in combination with other CFTR modulators across F508del genotype groups demonstrated the potential of NBD1 stabilizer-based combinations to benefit a broad population of people with CF WALTHAM, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
TAIRĀWHITI, New Zealand and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rua Bioscience Limited (NZX: RUA) (“Rua”) and PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla”) announce that Rua and PharmAla Biotech Inc., a subsidiary of PharmAla, have signed a distribution and licence agreement. Under the agreement, Rua will import, distribute and sell PharmAla’s pharmaceutical-grade LaNeo™ MDMA in New Zealand. The agreement follows Medsafe’s approval, on 4 September 2026, of two psy
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy (mFOLFOX6) in participants with previously untreated, HER2-negative, CLDN18.2-positive, and PD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (GEA), will be presented at the Europe
Lakefront Receives Transparency Notification from Bank of America
Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation 1 , Lakefront received a transparency notification, from Bank of America Corporation on October 6, 2026. The notification indicates that Bank of America Corporation, as controlling entity, crossed below the threshold of 10% of Lakefront’s voting rights on October 2, 202
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”). If consummated, the proposed transaction c
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced interim data from its Phase 1 clinical trial of ER-100 in three participants with open angle glaucoma (OAG). The data demonstrated that a single intravitreal administrati
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”). If consummated, the proposed transaction c